News | Point-of-Care Ultrasound (POCUS) | March 30, 2021

GE Healthcare Expands Ultrasound Family with New Point of Care System and AI Offering

Driven by pandemic realities and clinical demand for portable and intelligent point-of-care ultrasound (POCUS), GE Healthcare unveiled Venue Fit, a streamlined and compact POCUS system, alongside an industry-first articifical intelligence (AI) offering for cardiac imaging on the Venue and Venue Go

March 30, 2021 — Driven by pandemic realities and clinical demand for portable and intelligent point-of-care ultrasound (POCUS), GE Healthcare unveiled Venue Fit, a streamlined and compact POCUS system, alongside an industry-first artificial intelligence (AI) offering for cardiac imaging on the Venue and Venue Go. The Venue Fit is the smallest system in GE Healthcare’s Venue Family, featuring an easy-to-clean touchscreen, intuitive scanning tools, and a small footprint designed to fit in tight spaces often found in point-of-care settings.

The Venue Fit and associated AI come at a time where clinicians are relying on point of care ultrasound to combat the more than 127 million COVID-19 cases worldwide. Offering portability, real-time images, cleanability and workflow efficiency, POCUS has become an essential tool enabling clinicians to quickly triage and monitor patients in and outside of COVID wards. Accordingly, GE Healthcare saw orders for its existing Venue Go system increase more than fivefold in 2020 compared to the year prior.

“COVID-19 has had a huge impact on my practice as we’re currently seeing a surge in the emergency department, and I’ve been taking my Venue Go with me everywhere I go,” said Joseph Minardi, M.D., Chief of the Division of Emergency and Clinical Ultrasound and Director of the Center for Point-of-Care Ultrasound at a West Virginia academic medical center. “With the new Venue tools, I don’t have to struggle with the interface to be efficient. I can bring the device in with me, scan the patient, and using the Lung Sweep and RealTime EF (ejection fraction), I have the information I need right away.”

The new Venue Fit ultrasound system helps meet the needs of providers in tight spaces needing quick imaging insights. It’s smaller in size, but still provides the same Venue Family image quality, touchscreen, intuitive interface, and real-time documentation software that can save time and boost clinical confidence.

In addition to the release of the Venue Fit, the existing Venue Go and Venue ultrasound systems will now offer an industry-first AI tool for cardiac scanning with an integrated quality indicator, RealTime EF, alongside new software applications:

  • RealTime EF, the industry’s first AI tool that continuously calculates the heart’s real-time ejection fraction, a measurement of the heart’s ability to pump blood effectively, during live scanning with an integrated quality indicator that helps users know when they have an adequate view to generate accurate measurements of this critical cardiac measurement. The tool can help reduce the need for ECGs and support clinical confidence.
  • Lung Sweep, a rapid visualization tool that provides a dynamic panoramic view of the entire lung. This tool automatically activates at the start of each sweep when the probe is tapped on the body and deactivates at the end of each sweep when the probe is lifted, so there’s no need to touch the screen. The Auto B-lines tool can be used in conjunction with Lung Sweep to highlight B-lines over the entire panoramic view and display the frame with the most B-lines per rib space.
  • Renal Diagram, a simplified, intelligent documentation tool that allows clinicians to select labels from a prepopulated list that correlates with the images captured, making it easy for other clinicians to follow up on patients with suspected kidney infection.

“This past year we’ve seen point of care ultrasound take a prominent place at the bedside for clinicians, driven by its intuitive design and AI-powered diagnostic prowess,” said Dietmar Seifriedsberger, general manager of Point of Care Ultrasound at GE Healthcare. “Understanding healthcare’s growing resource constraints and the challenges of today’s world, we’re expanding our Venue Family and offerings to help improve our customer’s workflow efficiency and diagnostic confidence.”

For more information: https://venue-pocus.gehealthcare.com/

Find more POCUS news and video

Related Content

CDC and FDA Call for Pause on Janssen COVID-19 Vaccine Due to Rare Blood Clots #COVID19 #Janssen
Feature | Coronavirus (COVID-19) | April 15, 2021 | By Dave Fornell
April 15, 2021 — The U.S.
#SiemensHealthineers #Varian #Siemens The transformative combination accelerates the company’s impact on #global #healthcare and establishes a strong partner for #customers and #patients along the entire #cancer care continuum and for many of the most threatening #diseases
News | Radiology Business | April 15, 2021
April 15, 2021 — Siemens Healthineers AG an
Comparisons of high definition and standard definition infrared imaging for digital histopathology. Image courtesy of the Beckman Institute

Comparisons of high definition and standard definition infrared imaging for digital histopathology. Image courtesy of the Beckman Institute

News | Breast Imaging | April 14, 2021
April 14, 2021 — Detecting and analyzing breast cancer
A doctor reading #CXR scans using #SenseCare-Chest #DR Pro #diagnostic #software.

A doctor reading CXR scans using SenseCare-Chest DR Pro diagnostic software.

News | Artificial Intelligence | April 14, 2021
April 14, 2021 — SenseTime, a world-leading...
The U.S. Food and Drug Administration (#FDA) authorized marketing of #Medtronic's #GIGenius, the first device that uses #artificialintelligence (#AI) based on #machinelearning to assist #clinicians in detecting #lesions (such as #polyps or suspected tumors) in the #colon in real time during a c#olonoscopy.

The GI Genius intelligent endoscopy module works in real-time, automatically identifying and marking (with a green box) abnormalities consistent with colorectal polyps, including small flat polyps.

News | Artificial Intelligence | April 12, 2021
A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Image used with permission of RSNA.

A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Read more about this case study. Image used with permission of RSNA.

Feature | Coronavirus (COVID-19) | April 09, 2021 | By Dave Fornell, Editor
While the mass COVID-19 vaccinat
3-D mammography reduces the number of breast cancer cases diagnosed in the period between routine screenings, when compared with traditional mammography, according to a large study from Lund University in Sweden. The results are published in the journal Radiology.

Getty Images

News | Breast Imaging | April 09, 2021
April 9, 2021 — 3-D mammography reduces the number of breast cancer cases diagnosed in the period between routine scr
IV contrast-enhanced 2-mSv 4-mm-thick transverse and coronal (b) CT images show inflamed diverticula (arrows), segmental colonic wall thickening, and adjacent pericolic fat stranding. Image courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

IV contrast-enhanced 2-mSv 4-mm-thick transverse and coronal (b) CT images show inflamed diverticula (arrows), segmental colonic wall thickening, and adjacent pericolic fat stranding. Image courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Computed Tomography (CT) | April 09, 2021
April 9, 2021 — According to an open-acc...